Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis

Yun-Sheng Wang,^{1,2} Jun Ye,² Yong-Hong Cao,² Rong Zhang,² Yan Liu,² Su-Wan Zhang,² Wu Dai,² Qiu Zhang¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/postgradmedj-2018-136002>).

¹Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

²Department of Endocrinology, The Second People's Hospital of Hefei, Hefei, China

Correspondence to

Prof. Wu Dai, Department of Endocrinology, The Second People's Hospital of Hefei, Hefei 230011, China; daiwu1984@sina.com and Prof. Qiu Zhang, Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China; zhangqiu1965@sina.com

Y-SW and JY are joint first authors.

Received 13 July 2018
Revised 15 October 2018
Accepted 27 January 2019
Published Online First 27 March 2019

ABSTRACT

Objectives Fibroblast growth factor-21 (FGF-21) plays an important role in glucose and lipid metabolism. This study aims to systemically review the evidence regarding the relationship between the FGF-21 levels and type 2 diabetes mellitus (T2DM), as well as the related influential factors.

Methods Research related to plasma/serum FGF-21 levels in patients with T2DM and healthy controls were searched in PubMed, EMBASE and The Cochrane Library databases (up to 31 March 2017). Pooled standard mean difference (SMD) with 95% CI was calculated by fixed-effect or random-effect model analysis. Heterogeneity test was performed by the *Q*-statistic and quantified using *I*², and publication bias was evaluated using a funnel plot and Egger's linear regression test.

Results In total, 317 articles were obtained after searching databases, and 11 studies with 866 patients with T2DM and 629 controls were finally included. Meta-analysis revealed that, compared with the control group, the T2DM group had a significantly higher plasma/serum FGF-21 level ($p < 0.001$), with the SMD of 1.34% and 95% CI (0.70 to 1.98). Meta-regression analysis and subgroup analyses suggested that body mass index (BMI), triglycerides (TG) and total cholesterol (TC) were likely related to the observed FGF-21 differences between two groups.

Conclusions Overall, our study suggests that patients with T2DM have significantly higher plasma/serum FGF-21 levels, and the FGF-21 levels were influenced by BMI, TC and TG.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a group of metabolic diseases characterised by hyperglycaemia resulting from resistance to insulin action and an inadequate compensatory insulin secretory response.^{1,2} The chronic hyperglycaemia of diabetes could lead to a long-term damage of pancreatic function and cause an occurrence of diabetes complication which involved in various organs/tissue.² To some extent, the pathogenesis of T2DM is an interaction of multiple factors, of which insulin resistance, visceral adiposity, atherogenic dyslipidaemia, endothelial dysfunction, genetic susceptibility and elevated blood pressure are contributed to the onset of T2DM.³ The proinflammation in association with visceral obesity and insulin resistance inevitably leads to the substantial production of adipocytokines.⁴

Fibroblast growth factor-21 (FGF-21), a recently described member of the FGF family, plays important roles in regulating endocrine function and modulating metabolic processes.⁵ Serum FGF-21 is secreted predominantly by the liver and, to a lesser degree, by the adipose tissue in humans. It can function as a crucial regulator mediating beneficial metabolic effects of therapeutic agents such as metformin, glucagon/glucagon-like peptide 1 analogue.^{6,7}

Recent studies have disclosed the effect of FGF-21 on pancreatic islets, it could suppress cytokine-induced apoptosis in isolated rat pancreatic islets and increase insulin synthesis and promote glucose-induced insulin secretion from isolated diabetic rodent's islets.^{8,9} In addition, it has also been shown that treatment with FGF-21 is able to improve islet engraftment rates in experimental islet transplantation process,¹⁰ as well as improving lipoprotein profile and reducing body weight of diabetic rhesus monkeys.¹¹ In patients with T2DM, although FGF-21 concentrations have been assessed in some studies, the results are still not appearance consistent. This disparity in different reports may be attributed to no enough sample sizes, low statistical testing power, ethnic variations and/or clinical heterogeneity. In the present study, we conducted a systematic review and meta-analysis of published literatures in order to fully estimate the FGF-21 concentrations in patients with T2DM. Furthermore, we also explored and analysed whether certain factors, such as clinical and laboratory characteristics, have an effect on FGF-21 levels in T2DM.

METHODS

Search strategy

This systematic literature review and meta-analysis is strictly subject to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹²

We conducted a comprehensive literature search in electronic databases of PubMed, EMBASE and The Cochrane Library to obtain eligible studies published between database inception and 31 September 2017. We used Medical Subject Headings and other related keywords for search. The following terms were used in all fields: 'type 2 diabetes mellitus' OR 'T2DM' OR 'diabetes mellitus' AND 'fibroblast growth factor-21' OR 'fibroblast growth factor' OR 'FGF-21' OR 'FGF'.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Wang Y-S, Ye J, Cao Y-H, et al. *Postgrad Med J* 2019;**95**:134–139.

Figure 1 Flow chart of the systematic literature review. After excluding duplicate publication, unclear indicators, unmatched purposes, review and conference abstracts, 11 articles were included in the final analysis. FGF-21, Fibroblast growth factor-21; T1DM, type 1 diabetes mellitus.

All keyword variants were used to increase the number of studies returned by the search. Moreover, a manual search of reference lists was undertaken to look for additional relevant articles. There were no any language restrictions in the search strategy. If relevant information of published study was not available, we contacted the correspondence authors to obtain the additional information via email.

Inclusion criteria and exclusion criteria

For inclusion in the meta-analysis, all the following criteria had to be met: (1) published observational studies with data on both patients with T2DM and healthy age- and sex-matched controls and (2) study provided the detailed data about FGF-21 level in both cases and controls. The diagnostic criteria of T2DM were clearly defined, and healthy controls were clearly described. If study with data published more than once or using the same subjects, we considered all publications for data abstraction, only the article with adequate study strategy was chosen.

Study subjects with type 1 diabetes mellitus, pre-diabetes mellitus were excluded. In addition, studies were excluded if they were review articles, clinical trials, case report and discussion papers. We also excluded studies in which they reported ambiguous eligibility criteria. A flow chart regarding the process of studies identified, included and excluded is displayed in figure 1.

Data extraction

Quality assessment of each included studies was accessed and scored by two independent reviewers (Yun-Sheng Wang and Jun Ye) using the Newcastle-Ottawa Quality (NOS) Assessment Scale to determine the quality of selection of study participants, comparability, exposure and outcome.¹³ Disagreements were discussed, and further adjudication was resolved by a third reviewer (Rong Zhang).

We extracted the following data from each of included studies using a predesigned extraction form, which includes the following: first author's name, publication year, participant's age, sex proportion, body mass index (BMI), country study, study sample size (n), the concentration of FGF-21 in T2DM and controls, as well as other related information, respectively.

Statistical analysis

The effect size of mean FGF-21 difference between patients with T2DM and control was computed using standardised mean difference (SMD), and a forest plot was displayed to estimate the SMD and its 95% CIs.¹⁴ Heterogeneity of the included studies was tested by the Q -statistic¹⁵ and quantified using $I^2 = 100\% \times ((Q - \text{degree of freedom}) / Q)$.¹⁶ If I^2 value was more than 50% and the p value for the test of heterogeneity was <0.10 , the results were considered heterogeneous. If all the included studies shared a common effect size, then the fixed-effect model was applied. Otherwise, a random-effects model was used. Evidence of publication bias was assessed through a visual funnel plot and Egger's regression asymmetry test.¹⁷ Subgroup analysis was performed to detect the underlying sources of heterogeneity. All statistical analyses were conducted by Stata V. 12.0 software.

RESULTS

Study characteristics

Our initial search, from PubMed, EMBASE and The Cochrane Library databases, yielded 317 studies. In all, 290 articles were excluded from the study due to the following reasons: (1) not original articles, (2) not English articles, (3) duplicated articles, (4) case only studies, (5) not pertaining to T2DM, (6) not pertaining to FGF-21 and (7) no available data. Of the other 27 potential articles, 11 articles including 1495 subjects (866 patients with T2DM and 629 healthy controls) fulfilled all the inclusion criteria and were ultimately incorporated in this meta-analysis. The basic characteristics of included studies are further summarised in detail in Table 1.^{18–28} FGF-21 concentration was compared between patients with T2DM and age-, sex- and BMI-matched healthy controls in each included study. Quality assessment by NOS was determined among each included studies (online supplementary table 1) (table 1). The scores of all the included studies ranged from 5 to 8 stars and were considered a relative high quality.

Meta-analysis results

Heterogeneity test results

Heterogeneity was tested with Cochran's Q -statistic and quantified using I^2 . In this study, the heterogeneity across studies was statistically significant ($I^2=96.50\%$, $p<0.001$) (figure 2; meta-analysis of 11 studies reporting on FGF-21 in T2DM compared with controls).

Overall effects

Overall, the incorporate analysis showed that patients with T2DM have significantly higher levels of FGF-21 for a comparison of healthy controls (SMD=1.34, 95% CI: 0.70 to 1.98) (figure 2).

Meta-regression analysis and subgroup analysis

Meta-regression analysis was conducted to explore the potential heterogeneity sources. The effects of covariates on FGF-21 are shown in table 2, and the results showed that BMI, triglycerides (TG) and total cholesterol (TC) were all statistically significant covariates and associated with observed FGF-21 differences

Table 1 Characteristics of Abstracted studies

Author, year	Region	Patients with T2DM				Control				Study type	NOS			
		No.	Age (mean±SD) years	% female	BMI	FGF-21 level (pg/mL)	No.	Age (mean±SD) years	% female			BMI	FGF-21 level (pg/mL)	Measurement type
Akour <i>et al</i> , 2016	Jordan	103	51.0±3.8	NA	27.6	300	95	51.0±3.8	NA	32.7	200	ELISA	Case-control	8
Esteghamati <i>et al</i> , 2016 ¹⁹	Iran	44	55.0±12.0	52.3	30.6	103.5	42	53.5±14.0	59.5	25.8	99	ELISA	Cross-sectional	7
Shafaei <i>et al</i> , 2015 ²⁰	Iran	60	48.5±6.8	NA	32.9	622	60	52.2±9.8	NA	26.2	533.9	ELISA	Case-control	7
Lin <i>et al</i> , 2014 ²¹	China	117	60.3±10.2	46.2	24.9	542.3	68	58.5±11.3	45.6	25.7	125.9	ELISA	Case-control	8
Xiao <i>et al</i> , 2012 ²²	China	77	55.3±8.9	45.5	24.7	381.2	75	54.9±8.3	45.3	21.0	301.4	ELISA	Case-control	8
Wang <i>et al</i> , 2012 ²³	China	111	49.0±6.0	53.2	24.9	3210	87	51.0±10.0	52.9	23.7	1520	RIA	Cross-sectional	7
Jian <i>et al</i> , 2011 ²⁵	China	158	65.7±10.3	46.8	24.0	492.3	50	65.3±8.0	52	25.6	467.89	ELISA	Case-control	8
Cheng <i>et al</i> , 2011 ²⁵	China	54	55.0±11.0	42.6	24.2	361.8	35	53.0±11.0	54.3	23.2	185.89	ELISA	Case-control	7
Li <i>et al</i> , 2009 ²⁶	USA	30	58.8±6.8	60	23.5	1810	30	57.9±6.5	63.3	23.9	1520	RIA	Case-control	7
Chen <i>et al</i> , 2008 ²⁷	China	44	53.0±11.0	45	24.6	1820	35	48.0±12.0	43	24.7	1530	RIA	Case-control	7
Li <i>et al</i> , 2008 ²⁸	China	68	52.0±12.0	NA	33.3	2820	52	50.0±13.0	NA	23.3	2280	RIA	Case-control	7

BMI, body mass index; ELISA, enzyme-linked immunosorbent assay; NA, not available; NOS, Newcastle-Ottawa Scale; RIA, radioimmunoassay.

within study groups (all $p < 0.05$). However, no such association was observed for publication year, NOS score, measurement type, total sample size, high-density lipoprotein (HDL) and low-density lipoprotein (LDL). It suggested that BMI, TG and TC are the main effects of covariates contributing to the between-study heterogeneity.

Given the existence of heterogeneity, we also performed subgroup analysis, based on BMI, race, measurement options, TG, TC, HDL and LDL, to identify the possible source of heterogeneity across the studies. The lowest FGF-21 levels among those factors was in $TG < 150 \text{ mg/dL}$ (0.29 (95% CI: 0.06 to 0.52)) and the highest was $110 \text{ mg/dL} \leq TC < 220 \text{ mg/dL}$ (2.90, 95% CI: 0.92 to 4.02) followed by $BMI \geq 25$ (2.22, 95% CI: 0.42 to 4.02) (table 3). It suggested that BMI and TC were positively associated with FGF-21 in T2DM, whereas TG was negatively associated with FGF-21 in T2DM.

Publication bias

Publication bias was visually depicted by a funnel plot, which showed an unsymmetrical shape. Later, Egger's linear regression test was applied to statistically assess the asymmetry of the funnel plot,²⁹ and the results suggested that there was no significant publication bias as a whole ($t = 1.53$, $p = 0.161$) (figure 3).

Sensitivity analyses

Sensitivity analysis was performed through the leave-one-out analyses that assessed the key studies that had substantial impact on between-study heterogeneity. The results showed no significant change when each study was withdrawn separately ($p > 0.05$), suggesting that the results of this meta-analysis were stabilised in FGF-21 levels between patients with T2DM and controls (figure 4).

DISCUSSION

FGF-21, as a recently identified polypeptide hormone, is a novel member of FGF family. It is preferentially expressed in liver and has been identified as a potent regulator of glucose and lipid homeostasis.³⁰ Numerous animal-based studies have documented that FGF-21 possesses potent beneficial effects on glucose and lipid metabolism and insulin sensitivity without obvious adverse effects.^{11 31} Recent human studies showed that serum FGF-21 levels were increased in patients with T2DM than in healthy controls; however, reported findings on the association between circulating FGF-21 and T2DM remain scant and controversial.

In this meta-analysis, we retrospectively collected the data of FGF-21 concentration from 11 comparisons of populations with T2DM and controls, a total of 1495 subjects having FGF-21 measurements reported. The results of this meta-analysis showed that there is a statistically significantly higher FGF-21 level in patients with T2DM compared with controls. Heterogeneity analysis indicated that there was a marked heterogeneity among the studies. Heterogeneity represents the degree of results variation among different studies. Strong heterogeneity may derive from the inconsistent results between-study and lead to an impaired validity of the meta-analysis. Publication bias was not detected as a whole. In order to discover the possible influences for the source of heterogeneity, the meta-regression analysis was applied. By evaluating the race, publication year, NOS score, BMI, measurement type, total sample size, TC, TG, HDL and LDL as covariates, we found that BMI, TG and TC were likely related to the observed FGF-21 difference between two groups, suggesting the potential role resulting in strong heterogeneity.

Figure 2 Forest plot of combined FGF-21 levels between patients with T2DM and controls. Random-effects meta-analysis of OPG levels between patients with T2DM and controls. FGF-21, fibroblast growth factor-21; OPG, osteoprotegerin; T2DM, type 2 diabetes mellitus.

Furthermore, the results of subgroup analyses indicated that BMI and TC were positively associated with FGF-21 in T2DM, whereas TG was negatively associated with FGF-21 in T2DM. Nevertheless, given the limited data of included studies, we cannot explore the other possible positive findings.

In the current study, there are several potential limitations that should be considered when interpreting these results. First, given the limitation of incorporated studies, of which the part of studies did not have a waist circumference (WC) report,

therefore, the association between FGF-21 and WC cannot be fully understood. Second, due to the relatively low number of studies and the limited data, it may affect the stability of making conclusion. More articles with larger samples should be included to avoid potential bias. Third, the target literature search would be more intact if the efficiency of resource sharing could be improved as well to promote the credibility of the result. Fourth, different reagents and instruments for the detection of FGF-21 levels in studies included in this meta-analysis may have contributed to the heterogeneity. Furthermore, as a retrospective study, meta-analysis did not prove causation which is susceptible to the methodological deficiencies of the pooled studies.

Nevertheless, this meta-analysis also has its strengths. In compared with single-country studies, we enhanced generalisability by combining findings from 11 studies across two continents, it was able to give a more precise estimation on the relationship between FGF-21 levels and T2DM by increasing the statistical power and resolution through incorporating the results of independent analyses.

CONCLUSIONS

In the present study, we concluded that FGF-21 levels are higher in patients with T2DM than in controls, and it is influenced by BMI, TC and TG variables. However, based on the limited literatures, it is essential for us to carry out large-scale prospective

Table 2 Effects of covariates on FGF-21 difference

Covariates	Coefficient	SE	t	p Value	95% CI
Race	-2.734	1.212	-2.26	0.087	-6.100 to 0.631
Year	0.219	0.321	0.68	0.531	-0.067 to 1.110
NOS score	1.391	1.263	1.10	0.332	-2.115 to 4.898
BMI	0.488	0.169	2.88	0.045	0.017 to 0.958
Measurement type	1.564	1.450	1.08	0.341	-2.461 to 5.590
Total sample size	-0.015	0.011	-1.46	0.217	-0.045 to 0.013
TG	0.010	0.002	4.82	0.005	0.005 to 0.016
TC	-0.023	0.006	-4.20	0.008	-0.038, to 0.091
HDL	-0.030	0.033	-0.90	0.409	-0.116 to 0.055
LDL	0.007	0.014	0.52	0.623	-0.029 to 0.044

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NOS, Newcastle-Ottawa Quality; TC, total cholesterol; TG, triglycerides.

Table 3 Subgroup analysis of FGF-21 level in T2DM

Stratification group	N	SMD (95% CI)	Heterogeneity test			Publication bias	
			Q	p Value	I ² (%)	t	p Value
Total	11	1.34 (0.70 to 1.98)	286.50	<0.001	96.50	1.53	0.161
BMI							
BMI ≥25	4	2.22 (0.42 to 4.02)	215.84	<0.001	98.60	20.29	0.285
BMI <25	7	0.87 (0.46 to 1.29)	48.40	<0.001	87.60	−1.92	0.785
Combined	11	1.34 (0.70 to 1.98)	286.50	<0.001	96.50	1.53	0.161
Race							
Caucasian	4	0.85 (0.17 to 1.53)	34.18	<0.001	91.20	−9.66	0.394
Non-Caucasian	7	1.64 (0.68 to 2.60)	250.05	<0.001	97.60	19.09	0.071
Combined	11	1.34 (0.70 to 1.98)	286.50	<0.001	96.50	1.53	0.161
Measurement options							
ELISA	7	1.68 (0.72 to 2.65)	252.03	<0.001	97.60	18.99	0.068
RIA	4	1.77 (0.55 to 2.40)	29.04	<0.001	89.70	−11.50	0.251
Combined	11	1.34 (0.70 to 1.98)	286.50	<0.001	96.50	1.53	0.161
TG							
TG <150 mg/dL	3	0.29 (0.06 to 0.52)	1.94	0.379	0	−0.16	0.976
TG ≥150 mg/dL	6	1.89 (0.83 to 2.94)	217.91	<0.001	97.70	17.17	0.158
Combined	9	1.35 (0.57 to 2.13)	282.97	<0.001	97.20	1.35	0.220
TC							
TC <110 mg/dL	5	0.69 (0.17 to 1.21)	37.10	<0.001	89.20	−5.80	0.533
110 mg/dL ≤ TC < 220 mg/dL	4	2.90 (0.92 to 4.02)	215.84	<0.001	98.60	20.29	0.285
Combined	9	1.35 (0.57 to 2.13)	282.97	<0.001	97.20	1.35	0.220
HDL							
30 mg/dL < HDL < 77 mg/dL	9	0.84 (0.46 to 1.21)	73.95	<0.001	89.20	−8.00	0.237
HDL ≥77 mg/dL	1	2.09 (1.40 to 2.78)	0	—	—	—	—
Combined	10	1.32 (0.64 to 2.01)	283.22	<0.001	96.80	1.40	0.198
LDL							
LDL <120 mg/dL	7	0.71 (0.24 to 1.18)	61.14	<0.001	90.20	−5.74	0.504
LDL ≥120 mg/dL	3	1.83 (0.67 to 3.99)	170.11	<0.001	98.80	25.00	0.134
Combined	10	1.32 (0.64 to 2.01)	283.22	<0.001	96.80	1.40	0.198

BMI, body mass index; ELISA, enzyme-linked immunosorbent assay; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RIA, radioimmunoassay; SMD, standard mean difference; TC, total cholesterol; TG, triglycerides.

Figure 3 Funnel plot (with pseudo 95% CIs) with the SE of the FGF-21 difference plotted against the mean difference of FGF-21 of each study. Funnel plots of the relationship between the FGF-21 levels of individual studies and the precision of the study estimate. FGF-21, fibroblast growth factor-21; SMD, standard mean difference.

Figure 4 Sensitivity analyses by excluding one study at a time. Plot of sensitivity analysis by excluding one study each time and the pooling estimate for the rest of the studies.

studies to determine the precise relationships between FGF-21 and T2DM.

What is already known on the subject

- Fibroblast growth factor-21 (FGF-21) plays important roles in regulating endocrine function and modulates metabolic processes.
- Recent studies have disclosed the effect of FGF-21 on pancreatic islets, it could suppress cytokine-induced apoptosis in isolated rat pancreatic islets, and increase insulin synthesis and promote glucose-induced insulin secretion from isolated diabetic rodent's islets.
- Although the expression of FGF-21 in patients with T2DM has been studied in some studies, the results are still not appearance consistent.

Main messages

- Patients with type 2 diabetes mellitus (T2DM) have a significant higher fibroblast growth factor-21 (FGF-21) level than in healthy controls.
- Increased FGF-21 levels are associated with body mass index, total cholesterol and triglycerides in patients with T2DM.
- Publication year, Newcastle-Ottawa Quality score, measurement type, total sample size, high-density lipoprotein and low-density lipoprotein do not show any relation with FGF-21 levels

Current research questions

- Further large-scale prospective studies are needed to understand the association between fibroblast growth factor-21 (FGF-21) levels and type 2 diabetes mellitus (T2DM).
- The possible regulatory effect between FGF-21 and pancreatic function.
- Based on this study, is FGF-21 can be regard as a new marker/target for the diagnosis and clinical treatment of T2DM?

Contributors YSW, WD and QZ designed the study. YSW, JY and YHC collected data, RZ and YL performed the statistical analyses. YSW and SWZ drafted the manuscript. All authors read and approved the final manuscript. YSW and JY contributed equally to this work and should be considered co-first authors.

Funding This study was supported by Anhui Science and Technology Project (grant number 1604a0802099).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Kumana CR, Tan KCB, Cheung BM. Absolute benefits of empagliflozin in type 2 diabetes: a game changer? *Postgrad Med J* 2017;93:373–5.
- 2 Zaccardi F, Webb DR, Yates T, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgrad Med J* 2016;92:63–9.
- 3 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* 2011;11:98–107.
- 4 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006;116:1793–801.
- 5 Ornitz DM, Itoh N. Fibroblast growth factors. *Genome Biol* 2001;2:REVIEWS3005.
- 6 Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. *Physiol Res* 2009;58:1–7.
- 7 Kharitonov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. *BioDrugs* 2008;22:37–44.
- 8 Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. *Diabetes* 2009;58:250–9.
- 9 Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. *Endocrinology* 2008;149:6018–27.
- 10 Uonaga T, Toyoda K, Okitsu T, et al. FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. *Islets* 2010;2:247–51.
- 11 Kharitonov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. *Endocrinology* 2007;148:774–81.
- 12 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62:1006–12.
- 13 Robert K, Pagès C, Ledru A, et al. Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. *Neuroscience* 2005;133:925–35.
- 14 Wang P, Mao YM, Zhao CN, et al. Increased pulse wave velocity in systemic lupus erythematosus: a meta-analysis. *Angiology* 2018;69:228–35.
- 15 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- 16 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 17 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- 18 Akour A, Kasabri V, Boulatova N, et al. Levels of metabolic markers in drug-naïve prediabetic and type 2 diabetic patients. *Acta Diabetol* 2017;54:163–70.
- 19 Esteghamati A, Momeni A, Abdollahi A, et al. Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients. *Ann Endocrinol* 2016;77:586–92.
- 20 Shafaei A, Khoshnia M, Marjani A. Serum level of fibroblast growth factor 21 in type 2 diabetic patients with and without metabolic syndrome. *Journal of Medical Sciences* 2015;15:80–6.
- 21 Lin Y, Xiao YC, Zhu H, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. *J Diabetes Res* 2014;2014:1–6.
- 22 Xiao Y, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. *J Clin Endocrinol Metab* 2012;97:E54–E58.
- 23 Wang B, Yang G, Yang M, et al. Mitiglinide treatment may decrease plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. *Cytokine* 2012;57:300–3.
- 24 Jian W-X, Peng W-H, Jin J, et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. *Metabolism* 2012;61:853–9.
- 25 Cheng X, Zhu B, Jiang F, et al. Serum FGF-21 levels in type 2 diabetic patients. *Endocr Res* 2011;36:142–8.
- 26 Li K, Li L, Yang M, et al. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 2009;161:391–5.
- 27 Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes* 2008;116:65–8.
- 28 Li L, Yang G, Ning H, et al. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. *Diabetes Res Clin Pract* 2008;82:209–13.
- 29 Palma S, Delgado-Rodriguez M. Assessment of publication bias in meta-analyses of cardiovascular diseases. *J Epidemiol Community Health* 2005;59:864–9.
- 30 Sánchez J, Palou A, Picó C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. *Endocrinology* 2009;150:5341–50.
- 31 Kharitonov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. *J Clin Invest* 2005;115:1627–35.